Vertex Pharmaceuticals Incorporated Stock News

Vertex Pharmaceuticals (VRTX) closed at $435.82 in the latest trading session, marking a +1.31% move from the prior day.

This stock is already highly profitable with a huge cash stockpile thanks to a monopoly in its core niche market. It offers tremendous growth potential with multiple near-term catalysts.

Vertex Pharmaceuticals' work in cystic fibrosis isn't done yet. The company also stands to make headway in other areas over time.

Sarepta Therapeutics and Vertex Pharmaceuticals both go after rare diseases. Sarepta has made headway in its core area, but there is more work to be done.

From CRISPR gene editing to modify ideal agricultural traits, synthetic biology to promote eco-friendly engineering, or even that relating to biofuels, the field of biotechnology, also known as biotec

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Puma Biotech (PBYI) and Vertex Pharmaceuticals (VRTX). But which of these two stocks offers value in

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy

Vertex Pharmaceuticals (VRTX) reachead $439.70 at the closing of the latest trading day, reflecting a -0.09% change compared to its last close.

Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CR

Healthcare stocks remain a focal point for investors seeking stability and growth. The convergence of technology and an increased emphasis on global health has created an environment for ripe investme

Amazon's profits are improving significantly, and generative AI is providing it with a major ongoing tailwind. MercadoLibre has tremendous growth prospects in Latin America.

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $433.76, signifying a -0.85% move from its prior day's close.

This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.

The Food & Drug Administration has approved a second indication for a drug developed using a gene editing process called CRISPR. Casgevy, initially authorised in December for sickle cell disease trea

The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusio